British Journal of Pharmacology

CORRECTION

This correction provides additional author disclosures to six articles which all appeared in the *BJP* 174:10, May 2017 special issue themed section: Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors.

Sarwar M, Du X-J, Dschietzig TB, and Summers RJ (2017). The actions of relaxin on the human cardiovascular system. Br J Pharmacol 174: 933–949. https://doi.org/10.1111/bph.13523.

The author Thomas B Dschietzig is CEO and holds shares in Relaxera Pharmazeutische Gesellschaft mbH & Co. KG, a company dedicated to develop relaxin-2 (established July 2016) for chronic human cardio-vascular and metabolic therapeutic use and holding patents related to relaxin.

Patil NA, Rosengren K, Separovic F, Wade JD, Bathgate RAD, and Hossain MA (2017). Relaxin family peptides: structure–activity relationship studies. Br J Pharmacol 174: 950–961. https://doi.org/10.1111/bph.13684.

The authors Ross AD Bathgate, Mohammed A Hossain and John D Wade are inventors on an ongoing patent application related to this article, application PCT/AU2015/050184, Modified Relaxin B Chain Peptides.

Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, and Bennett RG (2017). Anti-fibrotic actions of relaxin. Br J Pharmacol 174: 962–976. https://doi.org/10.1111/bph.13529.

The author CS Samuel is one of inventors on patent CA 2967607 A1 related to the anti-apoptotic effects of relaxin/relaxin peptides.

Ivell R, Agoulnik AI, and Anand-Ivell R (2017). Relaxin-like peptides in male reproduction – a human perspective. Br J Pharmacol 174: 990–1001. https://doi.org/10.1111/bph.13689.

The author Alexander I Agoulnik is an inventor of patent WO 2003021266 A1, which is relevant to this publication.

Leo CH, Jelinic M, Ng HH, Marshall SA, Novak J, Tare M, Conrad KP, and Parry LJ (2017). Vascular actions of relaxin: nitric oxide and beyond. Br J Pharmacol 174: 1002–1014. https://doi.org/10.1111/bph.13614.

The authors LJ Parry and KP Conrad are co-inventors of patent WO 2011112791 A1 which relates to effects of relaxin in the kidney, brain and cervix.

Ang SY, Hutchinson DS, Patil N, Evans BA, Bathgate RAD, Halls ML, Hossain MA, Summers RJ, and Kocan M (2017). Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor. Br J Pharmacol 174: 1077–1089. https://doi.org/10.1111/bph.13522.

The authors Ross AD Bathgate and Mohammed A Hossain are inventors on an ongoing patent application related to this article, application PCT/AU2015/050184, Modified Relaxin B Chain Peptides.

DOI:10.1111/bph.14111